Upadoz 30 mg Tablet

Uses of Upadoz 30 mg Tablet

• Treatment of moderate to severe rheumatoid arthritis; may also be prescribed for other immune-mediated inflammatory conditions as per specialist advice (e.g.
• psoriatic arthritis
• ankylosing spondylitis
• atopic dermatitis
• ulcerative colitis) depending on approved indication and local labeling.

Key benefits

• Reduces joint pain and swelling
• Improves physical function and mobility
• Controls autoimmune inflammation
• Helps achieve/maintain remission or low disease activity
• Oral once-daily treatment option

How Upadoz 30 mg Tablet works

Upadacitinib is a Janus kinase (JAK) inhibitor (preferentially JAK1). It reduces inflammatory signaling by blocking cytokine pathways involved in immune activation, thereby decreasing pain, swelling and disease activity.

How to take Upadoz 30 mg Tablet

Oral tablet. Take exactly as prescribed, usually once daily, at the same time each day, with or without food. Swallow whole with water; do not crush/chew. If a dose is missed, take as soon as remembered on the same day; do not double the next dose.

Take it exactly as your doctor prescribed. Do not change the dose or stop early on your own.

Missed dose and overdose

If you miss a dose

If you miss a dose of Upadoz 30 Tablet ER, please consult your doctor.

If you take too much

Taking more Upadoz than prescribed can be harmful. If you suspect an overdose, contact a doctor or go to the nearest emergency department at once, and carry the pack or strip with you. In India the emergency number is 112.

Side effects of Upadoz 30 mg Tablet

Most side effects of Upadoz are mild and settle as the body adjusts. Reported side effects include:

• Upper respiratory tract infection
• nasopharyngitis
• nausea
• abdominal pain
• headache
• acne
• cough
• fever
• increased liver enzymes
• increased cholesterol
• herpes zoster

Stop the medicine and seek help immediately for a rash, swelling of the face or lips, wheezing or difficulty breathing. Tell your doctor about any side effect that persists or worries you.

Safety advice for Upadoz 30 mg Tablet

Warnings and precautions

Prescription-only immunosuppressant. Increased risk of serious infections (including TB, herpes zoster and opportunistic infections); screen for TB and viral hepatitis before starting and monitor. Risk of blood clots (DVT/PE), major cardiovascular events and malignancy reported with JAK inhibitors—use caution in patients with risk factors. Monitor CBC (low lymphocytes/neutrophils/hemoglobin), liver enzymes and lipids; stop/withhold in severe abnormalities. Avoid live vaccines during treatment; update immunizations before starting. Use caution in hepatic impairment; dose adjustments/avoidance may be needed as per label. Seek urgent care for signs of infection, chest pain, shortness of breath, leg swelling, severe abdominal pain or black stools.

Interactions with other medicines

Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) may increase levels; strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, St John’s wort) may reduce effect. Avoid combining with other potent immunosuppressants/biologics (e.g., other JAK inhibitors, TNF inhibitors, cyclosporine, azathioprine) unless directed by specialist. Live vaccines should be avoided.

How to store Upadoz 30 mg Tablet

Store below 30°C in a dry place, protected from light and moisture. Keep in original pack and out of reach of children.

Expert advice for Upadoz 30 mg Tablet

Before starting Upadoz 30 Tablet ER, the doctor will screen for infections, including tuberculosis, hepatitis B/C, and assess liver and renal function before initiating therapy. The doctor will monitor for signs of infection during treatment. Withhold therapy if a serious infection develops. Doctor administer necessary vaccinations before starting Upadoz 30 Tablet ER therapy. Avoid live vaccines during treatment. Tell your doctor about all medications you are taking to avoid potential drug-drug interactions. Inform your doctor if you currently smoke or have smoked in the past, as this medicine may increase the risk of certain cancers such as lymphoma or lung cancer.

Manufacturer and class

Manufacturer:

MSN LABORATORIES

Therapeutic class:

Immunomodulator (DMARD)

Drug class:

Janus kinase (JAK) inhibitor (JAK1 selective)

Chemical class:

Janus Kinase (JAK) inhibitors